Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Trofinetide

FDA approved · Rx

Synthetic IGF-1 tripeptide analog

Also known as: Daybue, Daybue Stix, NNZ-2566, DAYBUE, ACP-2566, trofinetida, trofinetidum, Glycyl-2-methyl-L-prolyl-L-glutamic acid

Evidence score

89/ 100

Strong evidence

Strong, human-grade evidence

Regulatory standing. FDA-approved prescription medicine
Human trials. Backed by controlled human studies
Registered human trials. 14 registered studies on ClinicalTrials.gov, most advanced Phase 3
2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Trofinetide is a synthetic analog of glypromate (glycine-proline-glutamate), a tripeptide fragment naturally cleaved from insulin-like growth factor 1 (IGF-1) in the brain. It is thought to act by reducing neuroinflammation and supporting synaptic function, though its exact mechanism is not fully understood. It is sold under the brand names Daybue and Daybue Stix.

What the evidence shows

Automatic summaryHuman trials

Trofinetide is FDA approved for the treatment of Rett syndrome in adults and children aged 2 years and older, based on Phase 3 trial results showing modest improvements on symptom rating scales. It has been studied in 14 registered human trials, and evidence for uses beyond Rett syndrome, such as other neurodevelopmental conditions, remains limited.